
Opinion|Videos|June 26, 2024
Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
The panel provides comprehensive insights on the treatment of ICANS following CAR T-cell therapy, highlighting the role of imaging, clinical trial data, and clinical pearls for community practices.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What do you consider best practices for the management of ICANS following CAR T-cell therapy?
- What are some strategies you can use to manage or mitigate ICANS in patients receiving CAR T-cell therapy?
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC
2
FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer
3
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
4
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
5


